Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from PCI Biotech Holding ASA ( (DE:4QG) ).
PCI Biotech has announced an update on its future operations following the discontinuation of its PCL technology development due to insufficient progress and increased project risks. The company is now focusing on evaluating a new bioprocessing technology and has initiated personnel downsizing and a wind-down of operations to align with this new focus. Strategic alternatives, including reverse mergers or a structured wind-down, are being explored to preserve value.
More about PCI Biotech Holding ASA
PCI Biotech is a biopharmaceutical company focused on developing and commercializing new technologies and novel therapies through its photochemical technology platform. Originating from research at the Oslo University Hospital, the platform was previously under development in two areas: photochemical lysis (PCL) for enhancing viral vector manufacturing and photochemical internalisation (PCI) for unlocking various modalities.
Average Trading Volume: 636,233
Current Market Cap: NOK13.06M
Learn more about 4QG stock on TipRanks’ Stock Analysis page.